This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TRAF4 / TNF receptor-associated factor 4 · IHC design guide
Design Immunohistochemistry for TRAF4
Plan TRAF4 staining in paraffin sections using glandular-cell positive controls and a tissue with undetected staining (HPA tissue IHC). The catalog antibody’s IHC dilution is 0.5–1 μg/ml (datasheet).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
TRAF4 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and membranous tissue staining (HPA tissue IHC) | |
| Staining pattern | Glandular cells show cytoplasmic and membranous signal (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Breast+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image PA2009) | |
| Caveat | Glandular-cell staining ranges from high to undetected by tissue (HPA tissue IHC) | |
| Regulation | Staining intensity varies by tissue (HPA tissue IHC) | |
| Isoform / epitope | 2 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended TRAF4 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published TRAF4 staining methods for human brain specimens (PMC6197255) and breast cancer tissue (PMC4414174).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet PA2009); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-TRAF4, 0.5-1μg/ml (datasheet PA2009) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | TRAF4-positive staining in glandular cells of breast (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic and membranous expression in several tissues. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 9.0 at 95–98 °C for 20 min (page antigen retrieval); compare the published citrate method (PMC4414174).
Section 2
What Is the Expected TRAF4 Staining Pattern?
For paraffin-section IHC, expect TRAF4 mainly in the cytoplasm and along cell membranes of selected epithelial cells, including breast and salivary gland glandular cells and urinary bladder urothelial cells (HPA: general cytoplasmic and membranous expression; High in these cells). Nuclear and perinuclear localization is also reported (UniProt Q9BUZ4: subcellular location). TRAF4 has no transmembrane segment (UniProt Q9BUZ4: topology). HPA rates tissue IHC reliability Enhanced, with medium consistency between staining and RNA data (HPA: reliability).
| Distinct cytoplasmic and membranous staining in breast or salivary gland glandular cells, or bladder urothelial cells. | This fits the reported tissue pattern; HPA scores these cell populations High, although that score is not a required intensity for every section (HPA: tissue IHC). Judge the labeled cells and their compartments together. |
| A section shows only strong staining in an unexpected compartment, with no matching cytoplasmic or membranous pattern. | Check for a localization or detection artefact before calling the result positive (HPA: tissue IHC pattern; UniProt Q9BUZ4: subcellular location). Nuclear staining alone is not automatically false: UniProt also lists nucleus, and HPA reports nucleolar and nucleoplasmic localization by ICC-IF (HPA: subcellular ICC-IF). |
| Cells reported as Not detected stain as strongly as expected-positive cells, such as adipocytes beside glandular cells. | Consider antibody cross-reactivity or endogenous detection activity and examine controls (HPA: adipocytes Not detected; breast glandular cells High). A tissue label alone is insufficient: HPA reports lymph-node germinal center cells as Not detected, while UniProt reports expression in lymph-node dendritic cells (HPA: tissue IHC; UniProt Q9BUZ4: tissue specificity). |
| Broad, hazy chromogen covers stroma, blank areas, and cells without a recognizable cellular pattern. | Treat this as background until controls clarify it; it does not match HPA's cell-associated cytoplasmic and membranous pattern (HPA: tissue IHC). In general IHC practice, examine blocking, antibody concentration, washes, and detection chemistry as possible contributors. |
| No signal appears in a chosen High-scoring control, such as salivary gland glandular cells. | A run-level sensitivity or detection problem is plausible; check section quality and controls before interpreting a study sample as negative (HPA: salivary gland glandular cells High). The HPA score describes reported staining and does not guarantee positivity in every specimen or assay. |
💡Expected TRAF4 appearanceCall a chromogenic section positive when identifiable glandular or urothelial cells show predominantly cytoplasmic and membranous staining consistent with HPA High examples; widespread cell-independent color or strong staining confined to reported Not detected cells warrants control review (HPA: tissue IHC).
| IHC evidence and antibody choice | HPA reports Enhanced tissue IHC reliability with medium staining–RNA consistency; its HPA052377 antibody has an Enhanced IHC validation entry (HPA: tissue IHC; HPA: antibodies). Match any comparison to the antibody and assay actually used; these ratings do not establish identical results for another reagent. |
| Cell and compartment selection | Use reported High populations as reference areas: breast, fallopian tube, gallbladder, salivary gland, or seminal vesicle glandular cells, and bladder urothelial cells (HPA: tissue IHC). HPA also scores bronchial respiratory epithelial cells Medium; do not require the same apparent intensity in every tissue (HPA: tissue IHC). |
| Topology and molecular forms | TRAF4 has no transmembrane segment, no signal peptide or propeptide, and a single annotated chain spanning residues 1–470 (UniProt Q9BUZ4: topology and processing). Membranous IHC staining therefore describes location, not evidence of a membrane-spanning TRAF4 form; antibody epitope coverage is unspecified. |
| Isoforms and modification | UniProt lists 2 isoforms and phosphoserine at residue 426 (UniProt Q9BUZ4: isoforms and modified residues). The supplied evidence does not show whether the IHC antibody distinguishes isoforms or phosphorylation states, so do not assign a staining difference to either. |
| IF/ICC Q: What localization is reported? | A: HPA reports the nucleoli fibrillar center as the main supported ICC-IF location, with supported nucleoplasmic and cytosolic locations; images are listed for HeLa, RT-4, U2OS, A-549, and MCF-7 (HPA: subcellular ICC-IF). This is a separate assay observation, not an IHC protocol or a requirement that paraffin sections show the same dominant compartment. |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected-positive glandular cells are blank. | The run may have insufficient staining or a detection failure; HPA reports these cells as High in several tissues, without guaranteeing every specimen (HPA: tissue IHC). | Check a concurrent positive control, antibody preparation, detection reagents, and the recorded retrieval conditions. Reassess the negative call only after the control works; no TRAF4-specific retrieval condition is supplied. |
| Every compartment and blank area looks brown. | Noncellular background can arise from general IHC workflow or endogenous detection activity; it does not match the reported cytoplasmic and membranous pattern (HPA: tissue IHC). | Inspect a no-primary control, then review blocking, washes, antibody concentration, and chromogen development using standard IHC controls. |
| Reported Not detected cells stain strongly. | Cross-reactivity or endogenous activity is possible; HPA reports adipocytes and bone-marrow hematopoietic cells as Not detected (HPA: tissue IHC). | Verify cell identity and compare with expected-positive cells and a no-primary control. Treat the unexpected signal as unresolved until those checks support specificity. |
| A nucleus-only result conflicts with the expected tissue IHC pattern. | HPA describes general cytoplasmic and membranous tissue staining, while nuclear locations are also reported by UniProt and HPA ICC-IF (HPA: tissue IHC and subcellular ICC-IF; UniProt Q9BUZ4: subcellular location). | Record the cell type and precise nuclear pattern, check controls, and compare assay context before calling it an artefact or a confirmed IHC pattern. |
| A low-signal specimen is called definitively TRAF4-negative. | HPA reports Low staining in several cell populations, including pancreatic exocrine glandular cells and skeletal-muscle myocytes; weak staining is harder to distinguish from assay limits (HPA: tissue IHC). | Use a High-scoring tissue control and score identifiable cells against background. Report the observed result and assay limits rather than inferring biological absence. |
| A negative result is blamed on fixation-specific TRAF4 epitope loss. | The supplied HPA and UniProt evidence does not report TRAF4-specific fixation sensitivity (HPA: tissue IHC; UniProt Q9BUZ4: record). | Document fixation and retrieval conditions, assess tissue integrity and run controls, and describe epitope loss only as an untested possibility. |
Experiment evidence
IHC & IF images showing TRAF4 staining
PA2009 · IHCAnti-TRAF4 antibody, PA2009, IHC(P) IHC(P): Rat Lymphonodus Tissue
PA2009 · IHCAnti-TRAF4 antibody, PA2009, IHC(P) IHC(P): Human Lung Cancer Tissue
M03069 · IFImmunofluorescent analysis using the Antibody at 1:150 dilution.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000076604-TRAF4/tissue/cerebral+cortex#imid_15951866
HPA · Salivary glandHuman Protein Atlas IHC, Salivary gland. Source: https://www.proteinatlas.org/ENSG00000076604-TRAF4/tissue/salivary+gland#imid_15951822
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000076604-TRAF4/tissue/colon#imid_15951406
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000076604-TRAF4/tissue/liver#imid_15951423
HPA · ICC-IF HeLaHuman Protein Atlas immunofluorescence, HeLa, antibody HPA021904; green = TRAF4, blue = nucleus, red = microtubules.
HPA · ICC-IF HeLaHuman Protein Atlas immunofluorescence, HeLa, antibody HPA021904; green = TRAF4, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for TRAF4 IHC & IF
🧪Run salivary gland first and score its glandular cells, which HPA rates High for TRAF4 (HPA: salivary gland glandular cells). Use appendix glandular cells as the tissue negative (HPA: Not detected); on the positive slide, document which non-glandular cells remain unstained rather than assuming they are TRAF4-negative.
Positive control tissue: Breast (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show TRAF4 in HeLa, RT-4, U2OS, A-549, MCF-7, with annotated localisation: Nucleoli fibrillar center (supported) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) slide and an isotype control matched to the primary antibody’s host species and clonality. Use TRAF4 knockout material, if available, as a biological negative; for chromogenic IHC, quench and check endogenous peroxidase activity in the salivary gland section before interpreting staining.
⚠️Feasibility: A TRAF4-specific fixation window and retrieval dependency are unreported in the supplied evidence, so optimize antigen retrieval empirically for the paraffin-section IHC assay. The selected PA2009 rat lymphonodus IHC(P) caption does not report a fixative (selected-SKU caption: fixative unreported). HPA reports ICC-IF images in HeLa, RT-4, U2OS, A-549 and MCF-7, but the supplied evidence does not establish that IF or frozen sections are easier than paraffin IHC (HPA: subcellular ICC-IF images); assess tissue background, including endogenous peroxidase, on the salivary gland control.
HPA tissue IHC evidence for TRAF4
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Fallopian tube | Glandular cells | High | Protein (IHC) | HPA → |
| Gallbladder | Glandular cells | High | Protein (IHC) | HPA → |
| Salivary gland | Glandular cells | High | Protein (IHC) | HPA → |
| Seminal vesicle | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Cervix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Hippocampus | Glial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced TRAF4 IHC Tips
Troubleshoot TRAF4 staining in chromogenic paraffin section IHC, using the selected retrieval setting and cell specific staining patterns as starting points.
How should I adjust retrieval when TRAF4 staining is weak or uneven?
Start with Tris-EDTA pH 9.0 heat retrieval at 95–98 °C for 20 min (page retrieval setting). Allow sections to cool in the buffer, then compare a known positive tissue and a negative control processed in the same run; high staining in salivary gland glandular cells offers a reference pattern (HPA: High in salivary gland glandular cells). If staining remains weak, test a shorter or longer heating interval on adjacent sections while keeping the buffer fixed. Assess tissue integrity and background alongside signal, because excessive heating can damage morphology and obscure compartment boundaries (standard IHC practice).
Could fixation explain weak TRAF4 staining in paraffin sections?
The PA2009 tissue IHC caption identifies rat lymphonodus tissue and IHC(P), but does not state a fixative (PA2009 tissue IHC caption). Consequently, TRAF4 sensitivity to a particular fixative or fixation duration is unknown from the supplied evidence. Record the actual fixative and processing history, then compare adjacent sections processed consistently while varying retrieval or detection conditions one at a time (standard IHC practice). Include a same-run positive control with an expected cellular pattern, such as salivary gland glandular cells (HPA: High in salivary gland glandular cells), before attributing a weak result to fixation.
Which compartments should contain convincing TRAF4 staining in IHC?
Evaluate cytoplasmic and membranous staining first, because the tissue IHC profile describes general expression in those compartments (HPA: tissue IHC profile). TRAF4 is also annotated in the nucleus, perinuclear cytoplasm, tight junctions, cell membrane and cytoskeleton (UniProt Q9BUZ4: subcellular location). Interpret a nuclear signal cautiously: supported nucleolar fibrillar center and nucleoplasmic locations come from cellular imaging evidence, not from the selected tissue IHC caption (HPA: subcellular). Compare compartment boundaries with a counterstain and assess adjacent cells within the same section (standard IHC practice). Diffuse color across tissue spaces without recognizable cells warrants a background check before scoring.
How can isoforms or epitope accessibility affect TRAF4 IHC?
TRAF4 has 2 annotated isoforms and a MATH domain spanning residues 307–462 (UniProt Q9BUZ4: isoforms and domains). Its annotated phosphoserine is at residue 426 (UniProt Q9BUZ4: modified residues). The supplied PA2009 caption gives no epitope sequence, so it cannot establish which isoforms the catalog antibody recognizes or whether phosphorylation affects binding (PA2009 tissue IHC caption). Check antibody epitope documentation before assigning a discrepant stain to splicing or modification; meanwhile, compare matched sections with identical Tris-EDTA pH 9.0 retrieval and include positive and omission controls (page retrieval setting; standard IHC practice).
How should I investigate TRAF4 localisation with a companion IF experiment?
Use IF as a companion assay to the chromogenic IHC result, and multiplex TRAF4 with a marker identifying the expected cell population, such as glandular cells in salivary gland (HPA: High in salivary gland glandular cells). Select a fluorophore channel after inspecting unstained tissue for autofluorescence, and include single-stain controls to assess channel bleed-through (standard IF practice). TRAF4 has no transmembrane segment and has annotated cytoplasmic and nuclear locations, so permeabilise sufficiently to expose intracellular epitopes while preserving morphology (UniProt Q9BUZ4: topology and subcellular location; standard IF practice). The supported nucleolar fibrillar center signal is cellular imaging evidence, not a required pattern for every IHC section (HPA: subcellular).
What should I check when TRAF4 staining appears widespread?
Compare the stained section with a primary-antibody omission control to identify detection-system background (standard IHC practice). For peroxidase detection, check that an endogenous peroxidase block was included and examine whether DAB deposits also occur in the omission control (standard chromogenic IHC practice). Titrate the primary antibody according to its documented range, and reassess blocking and wash stringency without assuming that broadly distributed color represents TRAF4 (standard IHC practice). General cytoplasmic and membranous expression across several tissues is reported, but cell-shaped, compartment-consistent staining still matters (HPA: tissue IHC profile). Evaluate glandular cells and surrounding tissue separately to locate the background source.
How should I score heterogeneous TRAF4 IHC across samples? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and scoring compartment before reviewing outcomes; HPA reports general cytoplasmic and membranous tissue staining (HPA: tissue IHC profile). For each region, record the percentage of positive cells and intensity, then calculate an H-score using 0–3 intensity bins and a 0–300 scale (standard IHC scoring practice). Where cellular composition varies, normalise positive-cell counts to the number of eligible cells; for spatial comparisons, report positive cells per mm² of viable tissue (standard image-analysis practice). Apply one threshold, exposure-independent review procedure and region-selection rule to all sections, and exclude folds, necrosis and obvious edge artifact before scoring (standard IHC practice).
How can I distinguish real TRAF4 staining from section artifacts?
A plausible positive follows recognizable cells and the expected cytoplasmic or membranous distribution in tissue IHC (HPA: tissue IHC profile). Check cell identity: glandular cells in salivary gland are reported High, whereas lymph-node germinal center cells are Not detected (HPA: tissue IHC). Do not treat the PA2009 rat lymphonodus caption as proof that every lymph-node cell type is positive, because it names the tissue without a cell-specific result (PA2009 tissue IHC caption). Reassess isolated staining confined to section edges or necrotic areas, and compare suspicious pigment with an omission control to detect endogenous enzyme or detection artifacts (standard IHC practice).
Boster reagents
Best TRAF4 / TNF receptor-associated factor 4 IHC Antibodies
Anti-TRAF4 options include paraffin-section IHC images from rat lymphonodus and human lung cancer tissue (PA2009 image captions), plus IF images with no specimen identified (M03069 image captions).
Real IHC data
Anti-TRAF4 Antibody ®
Cat # PA2009
Real IF data
Anti-TRAF4 Rabbit Monoclonal Antibody
Cat # M03069
PA2009 lists IHC for human, mouse, and rat, with paraffin-section images labeled rat lymphonodus and human lung cancer tissue (catalog applications/reactivity; PA2009 image captions). M03069 lists IF/ICC for human and mouse; its IF image captions do not identify a specimen (catalog applications/reactivity; M03069 image captions).
Which to pick: Choose PA2009 for tissue IHC: its IHC images identify paraffin sections, but do not report the fixative (PA2009 image captions). Choose M03069 for IF/ICC: it is a rabbit monoclonal, clone BGH-20, listed for both applications (catalog host/clone/applications). For cross-species work, PA2009 lists human, mouse, and rat reactivity for IHC; M03069 lists human and mouse reactivity for IF/ICC (catalog applications/reactivity).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9BUZ4 (TRAF4_HUMAN, TNF receptor-associated factor 4).
- Human Protein Atlas. TRAF4 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. TRAF4 subcellular location (ICC-IF): Mainly localized to the nucleoli fibrillar center. In addition localized to the nucleoplasm and cytosol..
- Human Protein Atlas. TRAF4 antibody validation summary (3 antibodies).
- Expression and Association of Tumor Necrosis Factor Receptor Associated Factor 4 (TRAF4) in Esophageal Squamous Cell Carcinoma. Medical science monitor : international medical journal of experimental and clinical research 2019 — PMC6455108.
- miR-29s function as tumor suppressors in gliomas by targeting TRAF4 and predict patient prognosis. Cell death & disease 2018 — PMC6197255.
- Overexpression of TRAF4 promotes lung cancer growth and EGFR-dependent phosphorylation of ERK5. FEBS open bio 2022 — PMC9527583.
- Cytoplasmic TRAF4 contributes to the activation of p70s6k signaling pathway in breast cancer. Oncotarget 2015 — PMC4414174.
- PubMed PMID:7490069 — UniProt-cited evidence.
- PubMed PMID:16625196 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for TRAF4 (TNF receptor-associated factor 4). Expected localisation Cytoplasmic and membranous tissue staining (HPA tissue IHC). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: PA2009 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Breast (Glandular cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet PA2009); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-TRAF4, 0.5-1μg/ml (datasheet PA2009); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image PA2009); Caveat: Glandular-cell staining ranges from high to undetected by tissue (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope coverage is unspecified (UniProt); Regulation: Staining intensity varies by tissue (HPA tissue IHC). Evidence: UniProt Q9BUZ4, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the nucleoli fibrillar center. In addition…, Datasheet PA2009, PMC6197255, PMC4414174. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/TRAF4/immunohistochemistry-ihc-guide.